Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1988 Nov;26(5):563–568. doi: 10.1111/j.1365-2125.1988.tb05296.x

Effect of intra-articular glucocorticoids on the disposition of sulphadimidine in chronic osteoarthritis patients.

P T Reeves 1, P Hanrahan 1, J Edelman 1, K F Ilett 1
PMCID: PMC1386633  PMID: 3207561

Abstract

1. The disposition of sulphadimidine (15 mg kg-1 orally) was investigated in six chronic osteoarthritis patients (four slow and two fast acetylators) prior to and 4 days following intra-articular administration of glucocorticoids. 2. The mean (+/- s.e. mean) renal clearance of sulphadimidine was increased from 0.03 +/- 0.01 to 0.07 +/- 0.02 ml min-1 kg-1 (P = 0.01) following the administration of intra-articular steroid. 3. Mean metabolic clearance and volume of distribution data were similar on the two study days. However, two of the slow acetylators showed marked increases (63% and 193%) in metabolic clearance following steroid treatment.

Full text

PDF
563

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bertouch J. V., Meffin P. J., Sallustio B. C., Brooks P. M. A comparison of plasma methylprednisolone concentrations following intra-articular injection in patients with rheumatoid arthritis and osteoarthritis. Aust N Z J Med. 1983 Dec;13(6):583–586. doi: 10.1111/j.1445-5994.1983.tb02608.x. [DOI] [PubMed] [Google Scholar]
  2. Boxenbaum H. Interspecies variation in liver weight, hepatic blood flow, and antipyrine intrinsic clearance: extrapolation of data to benzodiazepines and phenytoin. J Pharmacokinet Biopharm. 1980 Apr;8(2):165–176. doi: 10.1007/BF01065191. [DOI] [PubMed] [Google Scholar]
  3. Breckenridge A., Burke C. W., Davies D. S., Orme M. L. Immediate decrease by hydrocortisone of the plasma half-life of antipyrine. Br J Pharmacol. 1973 Feb;47(2):434–436. doi: 10.1111/j.1476-5381.1973.tb08344.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Bulovskaya L. N., Krupkin R. G., Bochina T. A., Shipkova A. A., Pavlova M. V. Acetylator phenotype in patients with breast cancer. Oncology. 1978;35(4):185–188. doi: 10.1159/000225282. [DOI] [PubMed] [Google Scholar]
  5. Chekharina YeA, Bulovskaya L. N., Pavlova M. V., Krupkin R. G. Activity of N-acetyltransferase in patients with malignant lymphomas. Neoplasma. 1978;25(4):471–475. [PubMed] [Google Scholar]
  6. Derendorf H., Möllmann H., Grüner A., Haack D., Gyselby G. Pharmacokinetics and pharmacodynamics of glucocorticoid suspensions after intra-articular administration. Clin Pharmacol Ther. 1986 Mar;39(3):313–317. doi: 10.1038/clpt.1986.45. [DOI] [PubMed] [Google Scholar]
  7. Edelman J., Potter J. M., Hackett L. P. The effect of intra-articular steroids on plasma salicylate concentrations. Br J Clin Pharmacol. 1986 Mar;21(3):301–307. doi: 10.1111/j.1365-2125.1986.tb05194.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Fine A., Sumner D. Alteration of hepatic acetylation in uraemia. Proc Eur Dial Transplant Assoc. 1975;11:433–440. [PubMed] [Google Scholar]
  9. Glowinski I. B., Radtke H. E., Weber W. W. Genetic variation in N-acetylation of carcinogenic arylamines by human and rabbit liver. Mol Pharmacol. 1978 Sep;14(5):940–949. [PubMed] [Google Scholar]
  10. Graham G. G., Champion G. D., Day R. O., Paull P. D. Patterns of plasma concentrations and urinary excretion of salicylate in rheumatoid arthritis. Clin Pharmacol Ther. 1977 Oct;22(4):410–420. doi: 10.1002/cpt1977224410. [DOI] [PubMed] [Google Scholar]
  11. Ilett K. F., David B. M., Detchon P., Castleden W. M., Kwa R. Acetylation phenotype in colorectal carcinoma. Cancer Res. 1987 Mar 1;47(5):1466–1469. [PubMed] [Google Scholar]
  12. Lee E. J., Lee L. K. A simple pharmacokinetic method for separating the three acetylation phenotypes: a preliminary report. Br J Clin Pharmacol. 1982 Mar;13(3):375–378. doi: 10.1111/j.1365-2125.1982.tb01388.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. McQueen C. A., Maslansky C. J., Glowinski I. B., Crescenzi S. B., Weber W. W., Williams G. M. Relationship between the genetically determined acetylator phenotype and DNA damage induced by hydralazine and 2-aminofluorene in cultured rabbit hepatocytes. Proc Natl Acad Sci U S A. 1982 Feb;79(4):1269–1272. doi: 10.1073/pnas.79.4.1269. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. McQueen C. A., Maslansky C. J., Williams G. M. Role of the acetylation polymorphism in determining susceptibility of cultured rabbit hepatocytes to DNA damage by aromatic amines. Cancer Res. 1983 Jul;43(7):3120–3123. [PubMed] [Google Scholar]
  15. Nakashima E., Yokogawa K., Ichimura F., Kurata K., Kido H., Yamaguchi N., Yamana T. A physiologically based pharmacokinetic model for biperiden in animals and its extrapolation to humans. Chem Pharm Bull (Tokyo) 1987 Feb;35(2):718–725. doi: 10.1248/cpb.35.718. [DOI] [PubMed] [Google Scholar]
  16. Notter D., Roland E. Localisation des N-acétyltransférases dans les cellules sinusoïdales hépatiques. Influence du zymosan sur l'acétylation de la sulfaméthazine et de l'isoniazide chez le rat et dans le foie isolé perfusé. C R Seances Soc Biol Fil. 1978;172(3):531–533. [PubMed] [Google Scholar]
  17. Olsen H., Mørland J. Ethanol-induced increase in drug acetylation in man and isolated rat liver cells. Br Med J. 1978 Nov 4;2(6147):1260–1262. doi: 10.1136/bmj.2.6147.1260. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Olsen H., Mørland J. Ethanol-induced increase in procainamide acetylation in man. Br J Clin Pharmacol. 1982 Feb;13(2):203–208. doi: 10.1111/j.1365-2125.1982.tb01357.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Reeves P. T., Minchin R. F., Ilett K. F. Induction of sulfamethazine acetylation by hydrocortisone in the rabbit. Drug Metab Dispos. 1988 Jan-Feb;16(1):110–115. [PubMed] [Google Scholar]
  20. Sarma G. R., Kailasam S., Nair N. G., Narayana A. S., Tripathy S. P. Effect of prednisolone and rifampin on isoniazid metabolism in slow and rapid inactivators of isoniazid. Antimicrob Agents Chemother. 1980 Nov;18(5):661–666. doi: 10.1128/aac.18.5.661. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Tanner A., Bochner F., Caffin J., Halliday J., Powell L. Dose-dependent prednisolone kinetics. Clin Pharmacol Ther. 1979 May;25(5 Pt 1):571–578. doi: 10.1002/cpt1979255part1571. [DOI] [PubMed] [Google Scholar]
  22. Vree T. B., Hekster Y. A., Damsma J. E., Tijhuis M., Friesen W. T. Pharmacokinetics and mechanism of renal excretion of short acting sulphonamides and N4-acetylsulphonamide derivatives in man. Structural requirements of sulphonamides for active tubular secretion. Eur J Clin Pharmacol. 1981;20(4):283–292. doi: 10.1007/BF00618779. [DOI] [PubMed] [Google Scholar]
  23. Weber W. W., Hein D. W. N-acetylation pharmacogenetics. Pharmacol Rev. 1985 Mar;37(1):25–79. [PubMed] [Google Scholar]
  24. White T. A., Evans D. A. The actylation of sulamethazine and sulfamethoxypyridazine by human subjects. Clin Pharmacol Ther. 1968 Jan-Feb;9(1):80–88. doi: 10.1002/cpt19689180. [DOI] [PubMed] [Google Scholar]
  25. Zídek Z., Janků I. Increased acetylation and elimination of sulphadimidine in rats with adjuvant induced arthritis. Eur J Drug Metab Pharmacokinet. 1981;6(4):255–259. doi: 10.1007/BF03189522. [DOI] [PubMed] [Google Scholar]
  26. du Souich P., Courteau H. Induction of acetylating capacity with complete Freund's adjuvant and hydrocortisone in the rabbit. Drug Metab Dispos. 1981 May-Jun;9(3):279–283. [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES